One case of drug-induced liver injury caused by Morodan

Published on Mar. 24, 2023Total Views: 2238 times Total Downloads: 1120 times Download Mobile

Affiliation: Department of Pharmacy, Shanghai Songjiang District Central Hospital, Shanghai 201600, China

Keywords: Morodan Drug-induced liver injury Adverse drug reactions

DOI: 10.19960/j.issn.1005-0698.202303014

Reference: Yue GAO, Yan-Li ZHANG.One case of drug-induced liver injury caused by Morodan[J].Yaowu Liuxingbingxue Zazhi,2023, 32(3): 356-360.DOI: 10.19960/j.issn.1005-0698.202303014.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

A 60-year-old female patient with chronic atrophic gastritis was treated with Morodan (16 pills, po, tid ), omeprazole (20 mg, po, bid ) and other drugs. After treatment, she developed symptoms such as fatigue, anorexia, greasy, yellow skin and sclera, and yellow urine. The liver function index was significantly increased, ALT 1 483 U·L^-1, AST 1 066 U·L^-1, AKP 351 U·L^-1, γ-GT 246 U·L^-1, TBil 28.4 μmol·L^-1, DBil 24.9 μmol·L^-1. The patient's liver function was normal before medication, and she had a history of liver function damage caused by Morodan. According to the Roussel Uclaf causality assessment method of drug-induced liver injury, the score was 9 points. It was considered that ‘most likely' was the drug-induced liver injury caused by Morodan. The liver function returned to normal after discontinuation of Morodan and liver protection treatment. Followed up for half a year, liver function indicators were normal.

Full-text

Please download the PDF version to read the full text: download

References

1. Teschke R, Eickhoff A. Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps[J]. Front Pharmacol, 2015, 23(6): 72. DOI: 10.3389/fphar.2015.00072.

2. Lee WM. Drug-induced acute liver failure[J]. Clin Liver Dis, 2013, 17(4): 575-586. DOI: 10.1016/j.cld.2013.07.001.

3. 孙成春, 徐建江. 152例药物性肝损伤临床分析[J]. 药物流行病学杂志, 2017, 26(6): 413-416. [Sun CC, Xu JJ. Clinical analysis of 152 patients with drug-induced liver injury[J]. Chinese Journal Pharmacoepmiology, 2017, 26(6): 413-416.] DOI: 10.19960/j.cnki.issn1005-0698.2017.06.010.

4. 柯小丽, 翟春颖. 154例药物性肝损伤患者的临床特点分析[J]. 临床合理用药杂志, 2021, 14(21): 168-170. [Ke XL，Zhai CY. Clinical characteristics of 154 patients with drug-induced liver injury[J]. Chinese Journal of Clinical Rational Drug Use, 2021, 14(21): 168-170.] DOI: 10.15887/j.cnki.13-1389/r.2021.21.062.

5. 高悦, 方维军, 张艳丽. 185例药物性肝损伤临床回顾性研究[J]. 药物流行病学杂志, 2019, 28(7): 439-443. [Gao Y, Fang WJ, Zhang YL. Retrospective study of 185 patients with drug-induced liver injury[J]. Chinese Journal Pharmacoepmiology, 2019, 28(7): 439-443.] DOI: 10.19960/j.cnki.issn1005-0698.2019.07.005.

6. 路燕, 陈明月, 郑秀良, 等. 185例药物性肝损伤患者的临床特征分析[J]. 安徽医学, 2022, 43(3): 308-313. [Lu Y, Chen MY, Zheng XL, et al. Clinical characteristics of 185 patients with drug-induced liver injury[J]. Anhui Medical Journal, 2022, 43(3): 308-313.] DOI: 10.3969/j. issn.1000-0399.2022.03.013.

7. 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J]. 中华肝脏病杂志, 2015, 23(10): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.

8. 高悦, 张艳丽. 摩罗丹（浓缩丸）致肝损伤3例[J]. 药物不良反应杂志, 2020, 22(9): 530-532. [Gao Y, Zhang YL. Liver injury due to moluodan concentrated pill: report of 3 cases[J]. Adverse Drug Reactions Journal, 2020, 22(9): 530-532.] DOI: 10.3760/cma.j.cn114015-20190909-00749.

9. 赵美, 杜春辉, 任秋霞, 等. 摩罗丹相关药物不良反应/不良事件3例[J]. 中国医院药学志, 2018, 38(20): 2191-2192. [Zhao M, Du CH, Ren QX, et al. Adverse drug reactions/adverse events related to Morodan: 3 cases [J]. Chinese Journal of Hospital Pharmcy, 2018, 38(20): 2191-2192.] DOI: 10.13286/j.cnki.chinhosppharmacyj. 2018.20.23.

10.丁紫薇. 摩罗丹药理作用及临床应用的研究进展[J].中国药物经济学, 2018, 13(9): 127-129. [Ding ZW. Advances in research on pharmacological effects and clinical application of MoLuodan[J]. China Journal of Pharmaceutical Economics，2018, 13(9): 127-129.] DOI: 10.12010/j.issn.1673-5846.2018.09.039.

11.药食同源目录大全(2020年最新版)[J]. 口腔护理用品工业, 2020, 30(1): 43-53. http://www.cnki.com.cn/Article/CJFDTotal-YGGY2020Z1014.htm.

12.中华医学会消化病学分会.中国慢性胃炎共识意见(2017年,上海)[J].胃肠病学, 2017, 22(11): 670-687. DOI: 10.3760/cma.j.issn.0254-1432.2017.11.001.

13.中华中医药学会脾胃病分会.慢性胃炎中医诊疗专家共识意见(2017)[J].中华中医药杂志, 2017, 32(7): 3060-3064. DOI: CNKI:SUN:BXYY.0.2017-07-063.

14.中国中西医结合学会消化系统疾病专业委员会.慢性萎缩性胃炎中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志, 2018, 26(2): 121-131. DOI: 10.3969/j.issn.1671-038X. 2018.02.03.

15.丁紫薇. 摩罗丹治疗慢性胃炎的安全性分析[J]. 中国药物经济学, 2017, 12(11): 15-18, 39. [Ding ZW. The safety analysis of Moluodan in the treatment of chronic gastritis[J]. China Journal of Pharmaceutical Economics, 2017, 12(11): 15-18, 39.] DOI: 10.12010/j.issn.1673- 5846.2017.11.003.

16.肖秀英, 张弋. 169例中草药致药物性肝损伤的文献分析[J]. 时珍国医国药, 2017, 28(4): 1022-1024. [Xiao XY, Zhang Y. Literature analysis of 169 cases of drug-induced liver injury caused by Chinese herbal medicine[J]. Shizhen and Materia Medica Research Mediciney, 2017, 28 (4): 1022-1024.] DOI: 10.3969/j.issn.1008-0805.2017. 04.093.

17.程玥, 丁泽贤, 张越, 等. 不同茯苓提取物对急性肝损伤小鼠的保护作用[J]. 安徽中医药大学学报, 2020, 39(4): 73-77. [Cheng Y, Ding ZX, Zhang Y, et al. Protective effect of different Poria cocos extracts against acute liver injury in mice[J]. Journal of Anhui University of Chinese Medicine, 2020,39(4): 73-77.] DOI: 10.3969/j.issn.2095-7246.2020.04.021.